SCHEMBL3487492

SCHEMBL3487492

CCCCCCCCCCCCCCCCOCC(COP(=O)(O)OCC(O)CO)OCCCCCCCCCCCCCCCC

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LPAR1 Q92633 9/20 0.68
▸ LPAR3 Q9UBY5 9/20 0.68
▸ LPAR2 Q9HBW0 6/20 0.60
▸ USP2 O75604 1/20 0.59
▸ LPAR5 Q9H1C0 6/20 0.58
▸ PLA2G2C Q5R387 1/20 0.52
▸ P2RY10 O00398 1/20 0.51
▸ LPAR6 P43657 5/20 0.50
▸ LPAR4 Q99677 5/20 0.50
▸ SELP P16109 1/20 0.48
▸ AKT1 P31749 3/20 0.47
▸ AKT2 P31751 3/20 0.47
▸ AKT3 Q9Y243 3/20 0.47
▸ PIK3R1 P27986 2/20 0.47
▸ PIK3CA P42336 2/20 0.47
▸ PLCG2 P16885 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31347418 1.00 LPAR1 (0.68) LPAR1LPAR3LPAR2USP2LPAR5
SCHEMBL31347412 1.00 LPAR1 (0.68) LPAR1LPAR3LPAR2USP2LPAR5
SCHEMBL31347445 1.00 LPAR1 (0.68) LPAR1LPAR3LPAR2USP2LPAR5
SCHEMBL31347433 1.00 LPAR1 (0.68) LPAR1LPAR3LPAR2USP2LPAR5
SCHEMBL31347450 1.00 LPAR1 (0.68) LPAR1LPAR3LPAR2USP2LPAR5
SCHEMBL31347451 1.00 LPAR1 (0.68) LPAR1LPAR3LPAR2USP2LPAR5
SCHEMBL31347443 1.00 LPAR1 (0.68) LPAR1LPAR3LPAR2USP2LPAR5
SCHEMBL31347421 1.00 LPAR1 (0.68) LPAR1LPAR3LPAR2USP2LPAR5
SCHEMBL29253735 0.99 LPAR1 (0.66) LPAR1LPAR3LPAR2USP2LPAR5
SCHEMBL3486664 0.93 P2RY10 (0.62) LPAR1LPAR3LPAR2USP2LPAR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746853-A1 A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) 2026-05-27 — — EP claimed
WO-2025021835-A9 A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-11-06 — — WO claimed
WO-2025021286-A1 A DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-01-30 — — WO claimed
WO-2025021835-A1 A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-01-30 — — WO claimed
US-9447127-B2 Synthetic lung surfactant and use thereof UNIVERSITY OF ROCHESTER (US) 2016-09-20 — — US claimed
EP-2812018-A2 NOVEL SP-B&SP-C PEPTIDES, SYNTHETIC LUNG SURFACTANTS, AND USE THEREOF University Of Rochester (US) 2014-12-17 — — EP claimed
US-20140044775-A1 SYNTHETIC LUNG SURFACTANT AND USE THEREOF UNIVERSITY OF ROCHESTER (US) 2014-02-13 — — US claimed
US-8563683-B2 Synthetic lung surfactant and use thereof UNIVERSITY OF ROCHESTER (US) 2013-10-22 — — US claimed
WO-2013120058-A2 NOVEL SP-B & SP-C PEPTIDES, SYNTHETIC LUNG SURFACTANTS, AND USE THEREOF UNIVERSITY OF ROCHESTER (US) 2013-08-15 — — WO claimed
US-20100055164-A1 SYNTHETIC LUNG SURFACTANT AND USE THEREOF UNIVERSITY OF ROCHESTER (US) 2010-03-04 — — US claimed
EP-2049554-A2 SYNTHETIC LUNG SURFACTANT AND USE THEREOF University of Rochester Medical Center (US) 2009-04-22 — — EP claimed
WO-2008011559-A2 SYNTHETIC LUNG SURFACTANT AND USE THEREOF UNIVERSITY OF ROCHESTER (US) 2008-01-24 — — WO claimed
EP-4746853-A1 A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) 2026-05-27 — — EP disclosed
WO-2025021835-A9 A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-11-06 — — WO disclosed
WO-2025021835-A1 A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-01-30 — — WO disclosed
WO-2025021286-A1 A DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-01-30 — — WO disclosed
WO-2013120058-A2 NOVEL SP-B & SP-C PEPTIDES, SYNTHETIC LUNG SURFACTANTS, AND USE THEREOF UNIVERSITY OF ROCHESTER (US) 2013-08-15 — — WO disclosed
US-20100055164-A1 SYNTHETIC LUNG SURFACTANT AND USE THEREOF UNIVERSITY OF ROCHESTER (US) 2010-03-04 — — US disclosed
EP-2049554-A2 SYNTHETIC LUNG SURFACTANT AND USE THEREOF University of Rochester Medical Center (US) 2009-04-22 — — EP disclosed
WO-2008011559-A2 SYNTHETIC LUNG SURFACTANT AND USE THEREOF UNIVERSITY OF ROCHESTER (US) 2008-01-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100055164-A1 SYNTHETIC LUNG SURFACTANT AND USE THEREOF PHOSPHO1, SGMS1, SMPD1 LPAR1 44/4885LPAR3 27/4885LPAR2 47/4885
US-20140044775-A1 SYNTHETIC LUNG SURFACTANT AND USE THEREOF PHOSPHO1, SGMS1, SMPD1 LPAR1 44/4885LPAR3 27/4885LPAR2 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback